Evidence map›Paper›PMID 39967949›Full record

ArticleArchives of medical science : AMS2024

Real-world prognostic factors in autotransplanted multiple myeloma patients with severe renal impairment: study of the Polish Myeloma Study Group.

Anna Waszczuk-Gajda, David H Vesole, Jolanta Małyszko, Artur Jurczyszyn, Tomasz Wróbel, Joanna Drozd-Sokołowska, Piotr Boguradzki, Krzysztof Mądry, Agnieszka Tomaszewska, Jarosław Biliński and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of medical science : AMS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Anna Waszczuk-GajdaDepartment of Haematology, Oncology, and Internal Medicine, Warsaw Medical University, Warsaw, Poland.
David H VesoleMyeloma Division, John Theurer Cancer Centre, Hackensack University Medical Centre, NJ, USA.
Jolanta MałyszkoDepartment of Nephrology, Dialysistherapy, and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
Artur JurczyszynDepartment of Haematology, Jagiellonian University Medical College, Krakow, Poland.
Tomasz WróbelDepartment and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
Joanna Drozd-SokołowskaDepartment of Haematology, Oncology, and Internal Medicine, Warsaw Medical University, Warsaw, Poland.
Piotr BoguradzkiDepartment of Haematology, Oncology, and Internal Medicine, Warsaw Medical University, Warsaw, Poland.
Krzysztof MądryDepartment of Haematology, Oncology, and Internal Medicine, Warsaw Medical University, Warsaw, Poland.
Agnieszka TomaszewskaDepartment of Haematology, Oncology, and Internal Medicine, Warsaw Medical University, Warsaw, Poland.
Jarosław BilińskiDepartment of Haematology, Oncology, and Internal Medicine, Warsaw Medical University, Warsaw, Poland.
Maria KrólDepartment of Haematology, Oncology, and Internal Medicine, Warsaw Medical University, Warsaw, Poland.
Longin NiemczykDepartment and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
Magdalena Olszewska-SzopaDepartment and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, Wroclaw, Poland.
Wieslaw W JedrzejczakDepartment of Haematology, Oncology, and Internal Medicine, Warsaw Medical University, Warsaw, Poland.
Grzegorz W BasakDepartment of Haematology, Oncology, and Internal Medicine, Warsaw Medical University, Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The prognostic factors in autotransplanted multiple myeloma (MM) patients with concomitant advanced chronic kidney disease (CKD) are poorly understood, limited, and controversial. Material and methods: We retrospectively analysed 44 patients with MM and CKD (eGFR < 40 ml/min), present both at diagnosis and at autologous stem cell transplantation (ASCT), with no improvement of renal function in-between. Results: Patients exhibiting deeper paraprotein responses to pre-transplant treatment predicted better response post ASCT (odds ratio (OR) = 11.6, Conclusions: Optimal patient selection including good performance status and higher albumin concentration (with every increase of 1 g/dl), chemotherapy-responsive disease pre-ASCT, melphalan dose adjusted to CKD, and intensive post-transplant supportive care are crucial to achieve acceptable results of treatment of MM patients with CKD.

Indexed as

advanced chronic kidney diseaseautologous stem cell transplantationdialysismultiple myeloma

Identifiers

PMID39967949
PMCPMC11831329

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.